Mechanisms of action of antiepileptic drugs

Current Topics in Medicinal Chemistry

Volumn 5, Issue 1, 2005, Pages 3-14

  Czapiński, Piotr ^a   Blaszczyk, Barbara ^b   Czuczwar, Stanislaw J ^c,d  

^a Center for Treatment of Epilepsy and Migraine   (Poland)

^b Neuropsychiatric Hospital Kielce   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Epilepsy; GABA; Glutamate; Ion channels

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; ANTICONVULSIVE AGENT; CALCIUM CHANNEL T TYPE; CALCIUM ION; CARBAMAZEPINE; CHLORIDE CHANNEL; CHLORIDE ION; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FREE RADICAL; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; LAMOTRIGINE; METABOTROPIC RECEPTOR; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RETIGABINE; SODIUM ION; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

4 AMINOBUTYRIC ACID UPTAKE; ANOREXIA; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BINDING SITE; BRAIN REGION; CALCIUM CURRENT; CALCIUM TRANSPORT; CHANNEL GATING; CHLORIDE TRANSPORT; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CONFUSION; DISEASE ACTIVITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ERUPTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EPILEPSY; FATIGUE; GABAERGIC SYSTEM; HEADACHE; HUMAN; HYPERPOLARIZATION; INHIBITION KINETICS; IRRITABILITY; LIVER FAILURE; MEMORY DISORDER; MENTAL DISEASE; MOUSE; NAUSEA; NERVE CELL; NERVE CELL STIMULATION; NERVOUSNESS; NONHUMAN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PSYCHOSIS; RAT; RECEPTOR BINDING; RESTLESSNESS; RETINA; RETINA DISEASE; REVIEW; SIDE EFFECT; SODIUM CURRENT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNAPSE; TOXIC EPIDERMAL NECROLYSIS; TREMOR;

ANIMALS; ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSY; EXCITATORY AMINO ACIDS; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA;

EID: 13444266427     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053386962     Document Type: Review

References (132)

1. Czuczwar, S.J.; Patsalos, P.N. The new generation of GABA enhancers. CNS Drugs 2001, 15,339-350.
2. Deckers, C.L.P.; Czuczwar, S.J.; Hekster, Y.A.; Keyser, A.; Kubova, H.; Meinardi, H.; Patsalos, P.; Renier, W.O.; van Rijn, C.M. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 2000, 41, 1364-1374.
3. Sobieszek, G.; Borowicz, K.K.; Kimber-Trojnar, Z.; Malek, R.; Piskorska, B.; Czuczwar, S.J. Zonisamide: A new antiepileptic drug. Pol. J. Pharmacol. 2003, 55, 683-689.
4. Antkiewicz-Michaluk, L. Receptor and voltage-operated ion channels in the central nervous system. Pol. J. Pharmacol. 1995 47, 253-264
5. Kostowski, W. Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Pol. J. Pharmacol. 1995, 47, 237-246.
6. C receptors. Vision Res. 1998, 38, 1431-1441.
7. Meldrum, B.S. Gamma-aminobutyric acid and the search for new anticonvulsant drugs. Lancet 1978, 2, 304-306
8. Schechter, P.J.; Tranier, Y.; Jung, M.J.; Böhlen, P. Audiogenic seizure protection by elevated brain GABA concentration in mice: Effects of γ-acetylenic-GABA and γ-vinyl-GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol. 1977, 45, 319-328
9. Kleinrok, Z.; Czuczwar, S.J.; Kozicka, M. Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 1980, 21, 519-529.
10. Czuczwar, S.J. Effect of combined with dopaminergic and GABA-ergic drugs on the threshold for maximal electroconvulsions in mice. Pol. J. Pharmacol. 1981, 33, 25-35.
11. Chapman, A.G.; Keane, A.P.; Meldrum, B.S.; Simiand, J.; Verniers, J.C. Mechanism of action of valproate. Prog. Neurobiol. 1982, 19, 315-359.
12. Bernasconi, R.; Klein, M.; Martin, P.; Portet, C.; Maitre, L.; Jones, R.S.G.; Baltzer, V.; Schmutz, M. The specific protective effect of diazepam and valproate against isoniazid-induced seizures is not correlated with increased GABA levels. J. Neural Transm. 1985, 63, 169-189.
13. Löscher, W. GABA and the epilepsies. Experimental and clinical considerations. In GABA. Basic Research and Clinical Applications; Bovery, N.G.; Nistico, G.; Eds.; Pythagora Press: Roma, 1989; pp 260-300.
14. Kalviainen, R.; Halonen, T.; Pitkanen, A.; Riekkinen, P.J. Amino acid levels in the cerebral fluid of newly diagnosed epileptic patients: effects of vigabatrin and carbamazepine. J. Neurochem. 1993, 60, 1244-1250
15. Petroff, O.A.C.; Rothman, D.L.; Behar, K.L.; Lamoreux, D.; Mattson, R.H. The effect of gabapentin on brain gamma-butyric acid in patients with epilepsy. Ann. Neurol. 1996, 39, 95-99.
16. Bialer, M.; Johanessen, S.I.; Kupferberg, H.J.; Levy, R.H.; Loisseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 1999, 34, 1-41.
17. Patsalos, P.N. New antiepileptic drugs. Ann. Clin. Biochem. 1999, 36, 10-19.
18. Meldrum, B.S.; Croucher, M.J.; Krogsgaard-Larsen, P. GABA-uptake inhibitors as anticonvulsant agents. In Problems in GABA Research: From Brain to Bacteria; Okada, Y.; Roberts, E.; Eds.; Excerpta Medica: Amsterdam-Oxford-Princeton, 1981; pp 182-191.
19. Löscher, W. New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 1998, 342, 1-13.
20. Löscher, W.; Hönack, D.; Taylor, C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci. Lett. 1991, 120, 150-154.
21. Meldrum, B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996, 37, Suppl. 6, S4-S11.
22. 2δ subunit of a calcium channel. J. Biol. Chem. 1996, 271, 5768-5776.
23. Shank, R.P.; Gardocki, J.F.; Vaught, J.L.; Davis, C.B.; Schupsky, J.J.; Raffa, R.B.; Dodgson, S.J.; Nortey, S.O.; Maryanoff, B.E. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994, 35, 450-460.
24. A receptor system. Epilepsia 1991, 32, 389-391.
25. Swinyard, E.A.; Sofia, R.D.; Kupferberg, H.J. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986, 27 27-34.
26. Marescaux, C.; Vergnes, M.; Depaulis, A. Genetic absence epilepsy in rats from Strasbourg: A review. J. Neural Transm. 1992, 35, 37-69.
27. Parker, A.P.; Agathonikou, A.; Robinson, R.O.; Panayiotopoulos, C.P. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. Dev. Med. Child Neurol. 1998, 40, 517-519.
28. Puigcerver, A.; van Luijtelaar, E.L.J.M.; Drinkenburg, W.H.I.M.; Coenen, A.M.L. Effects of the GABA-B antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. Brain Res. Bull. 1996, 40, 157-162.
29. Peeters, B.W.M.M.; van Rijn, C.M.; Vossen, J.M.H.; Coenen, A.M.L. Effects of GABA-ergic agents on spontaneous non-convulsive epilepsy, EEG and behaviour, in the WAG/Rij inbread strain of rats. Life Sci. 1989, 45, 1171-1176.
30. Meldrum, B.S. Amino acid neurotransmitters and new approaches to anticonvulsant drug action. Epilepsia 1984, 25, S140-S149.
31. Ben-Ari Y.; Lagowska, J.; Tremblay, E.; Le Gal LaSalle, G. A new model of focal status epilepticus: Intraamygdaloid application of kainic acid elicits repetitive secondarily generalized convulsive seizures. Brain Res, 1979, 163, 176-179.
32. Czuczwar, S.J.; Meldrum, B.S. Protection against chemically induced seizures by 2-amino-7- phosphono-heptanoic acid. Eur. J. Pharmacol. 1982, 83, 335-338.
33. Czuczwar SJ, Frey H-H, Löscher W. Antagonism of N-methyl-D,L-aspartic acid-induced seizures by antiepileptic drugs and other agents. Eur. J. Pharmacol. 1985, 108, 273-280.
34. Kleinrok, Z.; Czuczwar, S.J.; Turski, L. Prevention of kainic acid-induced seizure-like activity by antiepileptic drugs. Pol. J. Pharmacol. 1980, 32, 261-264.
35. Stone, W.E.; Javid, M.J. Effects of anticonvulsants and other agents on seizures induced by intracerebral L-glutamate. Brain Res. 1983, 264, 165-167.
36. Huxtable, R.J.; Laird, H.; Lippincott, S.E.; Wolson, P. Epilepsy and the concentration of plasma amino acids in humans. Neurochem. Int. 1983, 5, 125-135.
37. Croucher, M.J.; Collins, J.F.; Meldrum, B.S. Anticonvulsant action of excitatory amino acid antagonists. Science 1982, 216, 899-901.
38. Czuczwar, S.J.; Cavalheiro, E.A.; Turski, L.; Turski, W.A.; Kleinrok, Z. Phosphonic analogues of excitatory amino acids raise the threshold for maximal electroconvulsions in mice. Neurosci. Res. 1985, 3, 86-90.
39. Czuczwar, S.J.; Turski, L.; Schwarz, M.; Turski, W.A.; Kleinrok, Z. Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydantoin in mice. Eur. J. Pharmacol. 1984, 100, 357-362.
40. Turski ,W.A.; Urbaska, E.; Dziki, M.; Parada-Turska, J.; Ikonomidou, C. Excitatory amino acid antagonists protect mice against seizures induced by bicuculline. Brain Res. 1990, 514, 131-134.
41. Smith, S.E.; Durmuller, N.; Meldrum, B.S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 1991, 201, 179-183.
42. Turski, L.; Jacobsen, P.; Honoré, T.; Stephens, D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate antagonist 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline. J. Pharmacol. Exp. Ther. 1992, 260, 742-747.
43. Watkins, J.C.; Krogsgaard-Larsen, P.; Honoré, T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 1990, 11, 25-33.
44. Monaghan, D.T.; Bridges, R.J.; Cotman, CW. The excitatory amino-acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Ann. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
45. Zorumski, C.F.; Thio, L.L. Properties of vertebrate glutamate receptors: calcium mobilization and desensitization. Prog. Neurobiol. 1992, 39, 295-336.
46. 2+ channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists. Eur. J. Pharmacol. 1994, 264, 103-106.
47. Turski, L.; Niemann, W.; Stephens DN. Differential effects of antiepileptic drugs and carbolines on seizures induced by excitatory amino acids. Neuroscience 1990, 39, 799-807.
48. Pin, J.P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34, 1-26.
49. Bordi, F.; Ugolini, A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog. Neurobiol. 1999, 59, 55-79.
50. Nakanishi, S.; Nakajima, Y.; Masu, M.; Ueda, Y.; Nakahara, K.; Watanabe, D.; Yamaguchi, S.; Kawabata, S.; Okada, M. Glutamate receptors: brain function and signal transduction. Brain Res. Rev. 1998, 26, 230-235.
51. Adkins, J.C.; Noble, S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998, 55, 437-460.
52. Halonen, T.; Nissinen, J.; Jansen, J.A.; Pitkanen, A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur. J. Pharmacol. 1996, 299, 69-81.
53. Dalby, N.O.; Nielsen, E.B. Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat. Neurosci. Lett. 1997, 229, 135-137.
54. Dalby, N.O.; Nielsen, E.B. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res. 1997, 28, 63-72.
55. Sills, G.J.; Butler, E.; Thompson, G.G.; Brodie, MJ. Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study. Seizure 1999, 8, 404-411.
56. Lahtinen,H.; Ylinen, A.; Lukkarinen, U.; Sirvio, J.; Miettinen, R.; Riekkinen, P. Failure of carbamazepine to prevent behavioral and histopathological sequalae of experimentally-induced status epilepticus. Eur. J. Pharmacol. 1996, 297, 213-218.
57. Pitkanen, A.; Tuunanen, J.; Halonen, T. Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Epilepsy Res. 1996, 24, 29-45.
58. Hosford, D.A.; Wang, Y. Utility of the lethargic (lh/Ih) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997, 38, 408-414.
59. Luer, M.S.; Rhoney, D.H. Tiagabine: a novel antiepileptic drug. Ann. Pharmacother. 1998, 32, 1173-1180.
60. Knake, S.; Hamer, H.M.; Schomburg, U.; Oertel, W.H.; Rosenow, F. Tiagabine-induced absence status epilepticus in idiopathic generalized epilepsy. Seizure 1999, 8, 314-317.
61. Mecarelli, O.; De Feo, MR.; Del Priore, D. Vigabatrin versus carbamazepine and phenytoin in kainic acid-treated pubescent rats. Pharmacol. Res. 1997, 36, 87-93.
62. Engelborghs, S.; Pickut, B.A.; D'Hooge, R.; Wiechert, P.; Haegele, K.; De Deyn, P.P. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. Arzneimittelforschung 1998, 48, 713-716.
63. Mazurkiewicz, M.; Sirvio, J.; Riekkinen, P. Effects of single and repeated administration of vigabatrin on the performance of non-epileptic rats in a delayed non-matching to position task. Epilepsy Res. 1993, 15, 221-227.
64. Sidhu, R.S.; Del Bigio, MR.; Tuor, U.I.; Seshia, S.S. Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain. Exp. Neurol. 1997, 144, 400-405.
65. Arzimanoglou, A.A.; Dumas, C.; Ghirardi, L. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologist Sabril Study Group. Seizure 1997 6, 225-231.
66. Sheth, R.D.; Buckley, D.; Penney, S.; Hobbs, G.R. Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. Clin. Neuropharmacol. 1996, 19, 287-304.
67. Wohlrab, G.; Boltshauser, E.; Schmitt, B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998, 29, 133-136.
68. Siemes, H.; Brandl, U.; Spohr, H.L.; Volger, S.; Weschke, B. Long-term follow-up study of vigabatrin in pretreated children with West syndrome. Seizure 1998, 7, 293-297.
69. Provinciali, L.; Bartolini, M.; Mari, F.; Del Pesce, M.; Ceravolo, M.G. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurol. Scand 1996, 94, 12-18.
70. Mauguiere, F.; Chauvel, P.; Dewailly, J.; Dousse, N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 1997, 38, 301-308.
71. Thomas, L.; Trimble, M.; Schmitz, B.; Ring, H. Vigabatrin and behaviour disorders; a retrospective survey. Epilepsy Res. 1996 25, 21-27.
72. Kalviainen, R.; Nousiainen, I.; Mantyjarvi, M.; Nikoskelainen, E.; Partanen, J.; Partanen, K.; Riekkinen, P. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999, 22, 922-926.
73. Lawden, MC.; Eke, T.; Degg, C.; Harding, G.F.; Wild, J.M. Visual field defects associated with vigabatrin therapy. J. Neurol. Neurosurg. Psychiatry 1999, 67, 716-722.
74. Wild, J.M.; Martinez, C.; Reinshagen, G.; Harding, G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40, 1784-1794.
75. Versino, M.; Veggiotti, P. Reversibility of vigabatrin-induced visual field defect. Lancet 1999, 354 486.
76. Steinhoff, B.J.; Freudenthaler, N.; Paulus, W. The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication. Epilepsy Res. 1997, 29, 49-58.
77. Stefan, H.; Bernatik, J.; Knorr, J. Visual field defects due to antiepileptic drugs. Nervenarzt 1999, 70, 552-555.
78. Wohlrab,G.; Boltshauser, E.; Schmitt, B.; Schriever, S.; Landau, K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999, 30, 130-132.
79. Borowicz, K.K.; Swiader, M.; Luszczki, J.; Czuczwar, S.J. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: An isobolographic analysis. Epilepsia 1992, 43, 956-963.
80. De Sarro, G.; Spagnolo, C.; Gareri, P.; Gallelli, L.; De Sarro, A. Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur. J. Pharmacol. 1998, 349 179-185.
81. Bloms-Funke, P.; Löscher, W. The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. Eur. J. Pharmacol. 1996, 316, 211-218.
82. Kalviainen, R.; Keranen, T.; Riekkinen, P.J. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993, 46, 1009-1024.
83. Korn-Merker, E.; Borusiak, P.; Boenigk, H.E. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res. 2000, 38, 27-32.
84. Bialer, M.; Johanessen, S.I.; Kupferberg, H.J.; Levy, R.H.; Louiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002, 51, 31-71.
85. Swiader, M.; Kotowski, J.; Gasior, M.; Kleinrok, Z.; Czuczwar, S.J. Interaction of topiramate with conventional antiepileptic drugs in mice. Eur. J. Pharmacol. 2000, 399, 35-41.
86. Borowicz, K.K.; Luszczki, J.J.; Duda, A.M.; Czuczwar, S.J. Effect of topiramate on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy. Epilepsia 2003, 44, 640-646.
87. Cross, H. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002, 11, 406-410.
88. Macdonald, R.L.; Greenfield, L.J. Mechanisms of action of new antiepileptic drugs. Curr. Opin. Neurol. 1997, 10, 121-128.
89. Stefani, A.; Spadoni, F.; Bernardi, G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997, 38, 959-965.
90. Miller, A.A.; Wheatley, P.; Sawyer, D.A,; Roth, B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, I: anticonvulsant profile in mice and rats. Epilepsia 1986 27, 483-489.
91. Binnie, C.D.; Debets, R.M.; Engelsman, M.; Meijer, J.W.; Meinardi, H.; Overweg, J.; Peck, A.W.; Van Wieringen, A.; Yuen, W.C. Double-blind, cross-over trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989, 4, 222-229.
92. Loiseau, P.; Yuen, A.W.; Duche, B.; Menager, T.; Arne-Bes, M.C. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment with treatment resistant partial seizures. Epilepsy Res. 1990, 7, 136-145.
93. Buchanan, N. Lamotrigine in the treatment of absence seizures. Acta Neurol. Scand. 1995, 92, 348.
94. La Roche, S.M.; Helmers, S.L. The new antiepileptic drugs. JAMA 2004, 291, 605-614.
95. Klitgaard, H.; Pitkänen, A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 2003, 5 (Suppl. 1), S9-S16.
96. Dooley, M.; Plosker, G.L. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 2000, 60, 871-893.
97. Abou-Khalil, B.; Lazenby, B. Long-term experience with levetiracetam. Epileptic Disord. 2003, 5 (Suppl. 1), S33-S37.
98. Harty, T.P.; Rogawski, M.A. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000, 39, 47-55.
99. + channels from human and rat brain. Eur. J. Pharmacol. 1996, 316, 373-377.
100. DeSarro, G.; Ongini, E.; Bertorelli, R.; Aguglia, U.; DeSarro, A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur. J. Pharmacol. 1994, 262, 11-15.
101. Rho, J.M.; Donevan, S.D.; Rogawski, M.A. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and α-amino-butyric acid A receptors. Ann. Neurol. 1994, 35, 229-236.
102. McNamara, J.O. Kindling: an animal model of complex partial epilepsy. Ann. Neurol. 1984, 16, S72-S76.
103. Giorgi, O,; Carboni, G.; Frau, V.; Orlandi, M.; Valentini, V.; Feldman, A.C. Anticonvulsant effect of felbamate in the pentetrazole kindling model of epilepsy in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 354, 173-178.
104. Wlaz, P.; Löscher W. Anticonvulsant activity of felbamate in amygdala kindling model of temporal lobe epilepsy in rat. Epilepsia 1997, 38,1167-1172.
105. Ebert, U.; Reissmüller, E.; Löscher W. The new antiepileptic drugs lamotrigine and felbamate are effective in phenytoin-resistant kindled rats. Neuropharmacology 2000, 39, 1893-1903.
106. Harden, C.L. New antiepileptic drugs. Neurology 1994 44, 787-795.
107. Pellock, J.M. Felbamate in epilepsy therapy: evaluating the risk. Drug Saf. 1999, 21, 225-239.
108. Mellick, G.A. Hemifacial spasm: successful treatment with felbamate. J. Pain Sympt. Manag. 1995, 10, 392-395.
109. Winkler, S.R.; Luer M.S. Antiepileptic drug review: part 2. Surg. Neurol. 1998, 49, 566-568.
110. Sobieszek, G.; Borowicz, K.K.; Bimber-Trojnar, Z.; Malek, R.; Piskorska, B.; Czuczwar, S.J. Zonisamide: A new antiepileptic drug. Pol. J. Pharmacol. 2003, 55, 683-689.
111. Wellington, K.; Goa, K.L. Oxcarbazepine. An update of its efficacy in the management of epilepsy. CNS Drugs 2001, 15 137-163.
112. Gasior, M.; Carter, R.B.; Witkin, J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 1999, 20, 107-112.
113. Gasior, M.; Beekman, M.; Carter, R.B.; Goldberg, S.R.; Witkin,J.M. Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: comparison with diazepam and valproate. Drug Dev. Res. 1998, 44, 21-33.
114. Snead, O.C. Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann. Neurol. 1998, 44, 688-691.
115. Rundfeldt. C.; Rohlfs, A.; Netzer, R. Multiple actions of the new anticonvulsant D-23129 on voltage-gated inward currents and GABA-mediated currents in cultured neuronal cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 351 Suppl., R160.
116. ++ model in the hippocampal slice preparation. Epilepsy Res. 2000, 38, 53-66.
117. Vergnes, M.; Boehrer, A.; Simler, S.; Bernasconi, R.; Marescaux, C. Opposite effects of GABAb receptor antagonists on absences and convulsive seizures. Eur. J. Pharmacol. 1997, 332, 245-255.
118. B receptor antagonism on the development of pentylenctetrazol-induced kindling in mice. Brain Res. 1998, 809, 182-188.
119. B receptor antagonists on learning and memory retention in a rat model of absence epilepsy. Eur. J. Pharmacol. 1997, 320, 9-13.
120. Luszczki, J.J.; Czuczwar, M.; Kis, J.; Krysa, J.; Pasztelan, I.; Swiader, M.; Czuczwar, S.J. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: An isobolographic analysis. Epilepsia 2003, 44, 1003-1013.
121. Elger, C.E. Pharmacoresistance: Modern concept and basic data derived from human brain tissue. Epilepsia 2003, 44 (Suppl. 5), 9-15.
122. Czuczwar, S.J.; Turski, L.; Turski, W; Kleinrok, Z. Effects of some antiepileptic drugs in pentetrazol-induced convulsions in mice lesioned with kainic acid. Epilepsia 1981, 22, 407-414.
123. Czuczwar, S.J.; Turski, L.; Kleinrok, Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia 1982 23, 377-382.
124. Czuczwar, S.J.; Gasior, M.; Janusz, W.; Szczepanik, B.; Wlodarczyk, D.; Kleinrok, Z. Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice. Epilepsia 1990, 31, 318-323.
125. Gasior, M.; Borowicz, K.K.; Buszewicz, G.; Kleinrok, Z.; Czuczwar, S.J. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996, 37 262-268.
126. Gasior, M.; Borowicz, K.; Kleinrok, Z.; Czuczwar, S.J. Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock. Pharmacol. Biochem. Behav. 1996 54, 639-644.
127. Czuczwar, M; Kis, J.; Czuczwar, P.; Wielosz, M.; Turski, W. Nicotine diminishes anticonvulsant activity of antiepileptic drugs in mice. Pol. J. Pharmacol. 2004, 55, 799-802.
128. Kaufman, K.R.; Sachdeo, R.C. Caffeinated beverages and decreased seizure control. Seizure 2003, 12, 519-521.
129. Majkowski, J. Interactions between new and old generations of antiepileptic drugs. Epileptologia 1994, 2 (Suppl. 1 , 33-42.
130. Fröscher, W. Synergistic and additive effects of antiepileptic drugs in epileptic patients. Epileptologia 1998 6 (Suppl 2), 31-42.
131. Trojnar, M.K.; Malek, R.; Chroscinska, M.; Nowak, S.; Blaszczyk, B.; Czuczwar, S.J. Neuroprotective effects of antiepileptic drugs. Pol. J. Pharmacol. 2003, 54, 557-566.
132. Olney, JW.; Farber, N.B.; Wozniak, D.F.; Jevtovic-Todorovic, V.; Ikonomidou, C. Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain. Environ. Health Perspect. 2000, 108, 383-388.